Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals

Dow Jones

2024-12-03

By Denny Jacob

Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million.

Shares were trading 22% higher at around $1.67. The stock is down 59% on the year.

The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments.

Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses.

Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma.

The proposed transaction is expected to close by the end of the first quarter of 2025.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 03, 2024 07:40 ET (12:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2488911662"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488911662\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2488911662?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-03 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488911662","market":"sh","top_or_hot":-1,"title":"Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million. \n</p>\n<p>\n  Shares were trading 22% higher at around $1.67. The stock is down 59% on the year. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments. \n</p>\n<p>\n  Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses. \n</p>\n<p>\n  Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma. \n</p>\n<p>\n  The proposed transaction is expected to close by the end of the first quarter of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 03, 2024 07:40 ET (12:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-03 20:40</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million. \n</p>\n<p>\n  Shares were trading 22% higher at around $1.67. The stock is down 59% on the year. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments. \n</p>\n<p>\n  Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses. \n</p>\n<p>\n  Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma. \n</p>\n<p>\n  The proposed transaction is expected to close by the end of the first quarter of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 03, 2024 07:40 ET (12:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2488911662","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488911662","pubTimestamp":1733229600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million.Shares were trading 22% higher at around $1.67. The stock is down 59% on the year.The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments.Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses.Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma.The proposed transaction is expected to close by the end of the first quarter of 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4535":"淡马锡持仓","CHRS":"Coherus Biosciences"},"translate_title":"Coherus BioSciences股价因与Intas Pharmaceuticals达成剥离协议而上涨22%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHRS":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Coherus BioSciences shares rose in premarket trading after the company disclosed a divested franchise that would bring in up to $588.4 million. \n\n\n  Shares were trading 22% higher at around $1.67. The stock is down 59% on the year. \n\n\n  The commercial-stage biopharmaceutical company said it reached an agreement with Intas Pharmaceuticals for the divestment of its Udenyca franchise. The agreement includes an upfront payment of $483.4 million and $75 million in potential sales milestone payments. \n\n\n  Coherus said it plans to use a portion of the payment to fully repay the entirety of its $230 million in existing convertible notes due in April 2026, among other expenses. \n\n\n  Chief Executive Denny Lanfear said the deal positions Coherus to maximize the opportunity ahead for Loqtorzi, an FDA-approved treatment for nasopharyngeal carcinoma. \n\n\n  The proposed transaction is expected to close by the end of the first quarter of 2025. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2024 07:40 ET (12:40 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}